Hubert Borell

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.

Authors:

Ulrike Glaenzel Yi Jin Regine Hansen Kirsten Schroer Gholamreza Rahmanzadeh Ulrike Pfaar Jan Jaap van Lier Hubert Borell Axel Meissner Gian Camenisch Sylvia Zhao

Drug Metab Dispos 2020 10 14;48(10):873-885. Epub 2020 Jul 14.

PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., G.R., U.P., H.B., A.M., G.C., S.Z.); Preclinical Safety, Novartis Pharma AG, Basel, Switzerland (R.H.); Novartis Global Discovery Chemistry, Novartis Pharma AG, Basel, Switzerland (K.S., A.M.); and PRA Health Sciences, The Netherlands (J.J.v.L.).

View Article and Find Full Text PDF

October 2020

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.

Authors:

Alexander D James Hilmar Schiller Cyrille Marvalin Yi Jin Hubert Borell Ad F Roffel Ulrike Glaenzel Yan Ji Gian Camenisch

Pharmacol Res Perspect 2020 06;8(3):e00599

PK Sciences (ADME), Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF

June 2020

Metabolism and Disposition of Siponimod, a Novel Selective S1P/S1P Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.

Authors:

Ulrike Glaenzel Yi Jin Robert Nufer Wenkui Li Kirsten Schroer Sylvie Adam-Stitah Sjoerd Peter van Marle Eric Legangneux Hubert Borell Alexander D James Axel Meissner Gian Camenisch Anne Gardin

Drug Metab Dispos 2018 07 7;46(7):1001-1013. Epub 2018 May 7.

PK-Sciences, Novartis Pharma AG, Basel, Switzerland (U.G., Y.J., R.N., W.L., K.S., S.A.-S., E.L., H.B., A.D.J., A.M., G.C., A.G.), and PRA Health Sciences, Raleigh, North Carolina (S.P.M.).

View Article and Find Full Text PDF

July 2018

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.

Authors:

Yi Jin Hubert Borell Anne Gardin Mike Ufer Felix Huth Gian Camenisch

Eur J Clin Pharmacol 2018 Apr 22;74(4):455-464. Epub 2017 Dec 22.

PK Sciences, Novartis Institutes for Biomedical Research (NIBR), Fabrikstrasse 14, 202.3, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF

April 2018

CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.

Authors:

Yi Jin Markus Zollinger Hubert Borell Alfred Zimmerlin Christopher J Patten

Drug Metab Dispos 2011 Feb 2;39(2):191-8. Epub 2010 Nov 2.

Novartis Institutes for BioMedical Research, Drug Metabolism and Pharmacokinetics, Basel, Switzerland.

View Article and Find Full Text PDF

February 2011

Publications by authors named "Hubert Borell"

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.

Authors:

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.

Authors:

Metabolism and Disposition of Siponimod, a Novel Selective S1P/S1P Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.

Authors:

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.

Authors:

CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.

Authors: